Clinical Trial Update: Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic Fibrosis [Phase 1]

View source ↗

Summary

Phase 1 safety, pharmacokinetic and pharmacodynamic study of MP-376 in patients with cystic fibrosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• MP-376

Snippet

Sponsor: Amgen | Conditions: Cystic Fibrosis | Phase 1 | Status: COMPLETED